Authors: Al-kuraishy HM, Ali-Gareeb AI, Al-Niemi MS, Buhadily AK
PMID: 33623736 PMCID: PMC7883493 doi: 10.4103/JMAU.JMAU_63_20
Abstract
COVID-19 pathology is mainly associated to a pulmonary disease which sometimes might result in an uncontrollable storm related to inflammatory diseases which could be fatal. It is well known that phosphodiesterase enzyme type 5 inhibitors (PDE5Is), such as sildenafil, have been successfully developed for the treatment of pulmonary arterial hypertension; interestingly, more recently, it was shown that PDE5Is might be also anti-inflammatory. Therefore, it would be of interest to question about the use of PDE5Is to overcome the COVID-19 storm, as much as PDE5 is mainly present in the lung tissues and vessels.
Keywords: Acute lung injury, COVID-19, nucleotide phosphodiesterase enzyme
